AC BioScience announces the success of its application to the highly competitive Eurostars program. AC BioScience is the lead partner of a consortium that includes the Luxembourg Institute of Health (LIH) and Gustave Roussy Institute (IGR, France). The total European grant for the project amounts to EUR 850,000.
Andreas Schläpfer, Chairman of the Board and Co-founder of AC BioScience, said: "We are thrilled to obtain this European grant. This is a recognition of our ground-breaking scientific research and this will allow the company to accelerate the preclinical development of its immuno-oncology molecule ACB1801."
This molecule strongly increases the class-I antigen presentation and potentiates anti PD-1 efficacy in experimental models. It will be proposed for the treatment of MSI-L/MSS colorectal cancer patients in clinical trials in combination with the anti PD-1 pembrolizumab. The part accounted for by AC BioScience will be disbursed through Innosuisse.